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Background and Objectives: Platelets play a vital role in haemostasis but if activated 
inappropriately can contribute to cardiovascular disease (CVD) and result in myocardial 
infarction (MI) and/or stroke. Platelet hyperreactivity is linked to several diseases that are 
risk factors for CVD, including diabetes. The underlying cause of platelet hyperreactivity in 
diabetes is still largely unknown. The aim of this study was therefore (i) to investigate the 
effects of hyperglycaemia and thrombopoietin (TPO) on platelet function and (ii) to 
determine whether the anti-diabetes treatments, metformin and rosiglitazone affect platelet 
function. Experimental design: The effect of 100 ng/mL TPO, 25 mM glucose, 40 μM 
metformin and 100 μM rosiglitazone on platelet function were investigated. The functional 
assays include CRP-XL, PAR1-AP or thrombin stimulated platelet aggregation, integrin 
activation, phosphatidylserine exposure, reactive oxygen species generation, mitochondrial 
membrane potential depolarisation and calcium signalling. Results: Glucose alone had no 
effect on platelet aggregation but enhanced mitochondrial membrane depolarisation and PS 
exposure. TPO significantly enhanced platelet aggregation, mitochondrial membrane 
depolarisation, ROS generation and PS exposure. Metformin had no significant effect on 
platelet aggregation, whereas Rosiglitazone significantly reduced platelet aggregation but 
also significantly increased PS exposure and ROS generation. Conclusion: Hyperglycaemia 
and TPO contribute to a pro-coagulant platelet phenotype via increased PS exposure, 
providing a potential explanation for the platelet hyperreactivity observed in patients with 
diabetes and other diseases associated with chronic hyperglycaemia and elevated serum 
levels of TPO. Rosiglitazone has both anti-platelet and pro-coagulant properties. The latter 
of which, with further research, could provide an explanation behind the increase risk of 











Cardiovascular diseases (CVD) are disorders of the heart and blood vessels and are the 
most common cause of morbidity and mortality in the world, causing approximately 17.9 
million deaths worldwide every year (WHO, 2017). Some examples of CVD are; 
cerebrovascular disease, coronary heart disease and peripheral arterial disease. There are 
several risk factors that enhance the likelihood of developing CVD and a vast majority of 
them are lifestyle choices e.g. smoking, obesity, fatty diet, high cholesterol, high blood 
pressure and physical inactivity. However, other non-lifestyle caused factors include genetic 
predisposition factors and diabetes (World Heart Federation, 2017).  
Myocardial infarction (MI) and stroke are the main cause of death for patients with CVD 
and they are usually as a direct effect of atherosclerosis, which is when the build-up of 
atheroma causes narrowing of the arteries and prevention of blood, and therefore oxygen, 
reaching the heart or brain. Platelets play an important role in haemostasis and contribute to 
events which can lead to thrombosis and atherosclerosis.  Therefore, in patients with an 
already increased risk of developing CVD, platelet hyperreactivity is potentially life 
threatening.  
Platelet activation 
Platelets are the smallest cellular component of the blood and are produced by 
megakaryocytes in the bone marrow. Platelets initiate the haemostatic process and play a 
major role in the development of arterial thrombosis. At the site of vascular injury platelets 
bind to sub endothelial components such as collagen, which are otherwise hidden, which in 
turn induces platelet activation and fibrin formation (Fig. 1). This is an important process that 
is required to prevent excessive blood loss. However, platelet activation and thrombus 
formation can be a life-threatening process if it occurs inappropriately. For example, at the 
site of atherosclerotic plaque rupture where platelet aggregation leads to clot formation 
which can in turn lead to vascular occlusion and ischemic infarction.  
Under normal circumstances, platelets circulate the body through vessels with an intact, 
healthy endothelium in their original, inactivated state. Endothelium production of nitric oxide 
(NO) and prostacyclin and the absence of platelet activating factors supports this state. 
However, at the site of endothelial injury, the endothelium is no longer inhibiting platelet 
function and platelets are exposed to sub endothelial components such as collagen which 
binds to platelets (Fig. 1). Platelet activation occurs immediately after platelet adhesion and 
results in numerous functional changes including; exocytosis of secretory granules, shape 





Figure 1: Thrombus formation. At the site of vascular injury platelets adhere to subendothelial 
components such as collagen and Von Willebrand factor (a) resulting in platelet activation and 
secretion (b) of platelet mediators such as thrombin, thromboxane A2 and ADP (c) which results in 
additional activation (d) and recruitment of platelets (e) fibrils of fibrin form around the aggregation 
providing stability (f) and formation of the haemostatic plug. Intact endothelium will no longer be 
exposing platelet activating molecules and will also be releasing, prostacyclin and NO (g) which will 
inhibit further platelet activation. Figure from (Berridge, 2014; Natarajan, Zaman & Marshall, 2008). 
 
surface of platelets and when a platelet is activated this integrin is converted to a 
conformational state that has high affinity for fibrinogen from one with a low affinity for 
fibrinogen (Fig. 2). Fibrinogen can bind to two receptors at a time and is therefore able to 
cross-link platelets, ultimately resulting in platelet aggregation. These activated integrins are 
also able to bind to sub endothelial von Willebrand factor (vWF) to further anchor the 
platelets and provide additional clot stabilisation (Ginsberg, 2014).  
There are several different receptors on the surface of the platelet that when bound to 
by an agonist will initiate platelet activation via a wide variety of signalling pathways. 
Platelets can respond to an array of mediators since they express such a large, diverse and 
dynamic range of receptors from at least 9 protein super-families (Fig. 2). For this study I will 
mainly be focusing on protease activated receptor 1 activating peptide (PAR1-AP), 




Figure 2: An outline of the main receptors and signalling pathways involved in platelet activation 
including the receptors for CRP-XL (GPVI), PAR1-AP (PAR1) and thrombin (PAR1/PAR4). PLC, 
phospholipase C. PKC, protein kinase C. IP3, inositol-1,4,5-trisphosphate. TxA2, thromboxane A2. 
AKT, protein kinase B. cAMP, cyclic adenosine monophosphate. COX-1, cyclooxygenase-1. ADP, 
adenosine diphosphate. AA, arachidonic acid. ASA, aspirin.  Figure from: (Stalker, Newman, Ma, 
Wannemacher & Brass, 2012)  
 
Phosphatidylserine exposure 
Phosphatidylserine (PS) is a phospholipid and a component of the cell membrane. In the 
plasma membrane of a cell, phospholipids are not homogeneously spread across both 
leaflets of the membrane bilayer. In a resting cell (non-activate, non-apoptotic) neutral, 
choline-containing phospholipids such as: phosphatidylcholine and sphingomyelin are 
located on the outer leaflet. Whereas the negatively-charged phospholipids including: 
phosphatidylinositol and PS are actively held on the inner (cytosolic side) leaflet of the cell 
membrane (Bevers, Comfurius & Zwaal, 1983; Bevers & Williamson, 2010). However, under 
certain conditions such as when a cell undergoes apoptosis these negatively charged 
phospholipids are no longer restricted to the inner leaflet resulting in a large proportion of 
the PS being exposed on the outer leaflet this is known as the scrambling process (van 
Kruchten et al., 2013). 
PS exposure in platelets has predominately been associated with apoptosis 
(Gyulkhandanyan, Mutlu, Freedman & Leytin, 2012). It has also been reported that platelets 
stimulated with both CRP-XL and thrombin can lead to a platelet phenotype that is 
associated with increased PS exposure and enhanced platelet coagulation (Lentz, 2003). 
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Dual stimulated platelet activation leads to significantly increased cytosolic calcium 
concentration which in turn results in mitochondrial overload and the formation of 
mitochondrial permeability transition pores (MPTP). An increase in MPTP formation causes 
a reduction in mitochondrial membrane integrity and an increase in mitochondrial 
membrane depolarisation which results in a decrease in ATP and an increase in reactive 
oxygen species (ROS) generation. Mitochondrial membrane depolarisation can also lead to 
even further increases in cytosolic calcium levels, PS exposure and a reduction in plasma 
membrane integrity (Jackson & Schoenwaelder, 2010). There are two pathways which 
regulate PS exposure. Agonist stimulation leads to a calcium-dependent, caspase-
independent pathway resulting in PS exposure and this form of PS exposure is essential for 
platelet thrombin generation. Whereas the Bak/Bax-caspase-mediated PS exposure 
pathway is independent of platelet activation and is associated with necrosis 
(Schoenwaelder et al., 2009). Scott syndrome is a rare bleeding disorder, characterised by 
delayed haemostasis and wound healing, this is caused by the absence of the 
transmembrane protein 16F which leads to disrupted scramblase activity and the inability to 
expose PS (Zwaal, Comfurius & Bevers, 2004). At present, the only treatment available for 
patients with Scott syndrome is transfusion of normal platelets. Scott syndrome highlights 
the importance of PS exposure in haemostasis.  
Platelet exposure of PS is an important part of the blood coagulation process. Blood 
coagulation occurs at the same time as platelet activation and includes a series of inactive 
factors being converted to an active proteolytic enzyme which results in the conversion of 
prothrombin to thrombin. Thrombin is then responsible for converting fibrinogen to fibrin. As 
the fibrils of fibrin form, activated platelets are trapped, forming a clot (Wolberg, 2007). 
Coagulation reactions also enhance platelet activation by releasing thrombin. Platelet 
activation and coagulation systems tend to be mutually reinforcing with each inducing the 
other to form the final clot. Although agonist-induced PS exposure exhibits the same 
characteristics as apoptotic platelets, the mechanism that regulates their formation is 
different. At present it is unclear whether PS exposure in apoptotic platelets has any 
relevance to thrombin generation in vivo. It is likely that the externalisation of PS in 
apoptotic platelets acts as a recognition determinant for clearance by phagocytosis, as it 
does in other cells such as lymphocytes  (Fadok, Voelker, Campbell, Cohen, Bratton & 
Henson, 1992). 
Platelet hyperreactivity 
Overly reactive platelets can be linked to several different diseases and there is 
increasing evidence to suggest that increased platelet reactivity can identify patients that 
are at greater risk of CVD. There are numerous studies that have linked increased platelet 
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function with worse clinical outcomes in various cardiovascular settings (Kabbani, Watkins, 
Ashikaga, Terrien, Sobel & Schneider, 2003; Puurunen et al., 2018; Trip, Cats, van Capelle 
& Vreeken, 1990). Platelet hyperreactivity has been associated with several diseases 
including; unstable angina (UA), chronic kidney disease, chronic obstructive pulmonary 
disease, peripheral arterial disease and diabetes (Gremmel et al., 2013; Maclay et al., 2011; 
Robless, Okonko, Lintott, Mansfield, Mikhailidis & Stansby, 2003); (Gaiz, Mosawy, Colson & 
Singh, 2017; Lupia et al., 2006) 
Diabetes Mellitus 
Overview 
Diabetes mellitus (DM) is a chronic disease and it is estimated that 1 in 11 adults 
worldwide are diagnosed with DM (Zheng, Ley & Hu, 2018). DM occurs when the pancreas 
doesn’t produce enough insulin (type 1) or the body cannot respond effectively to insulin 
(type 2). Insulin is a hormone that is released from the pancreas and is important for 
controlling blood sugar levels. Under normal circumstances an increase in blood glucose 
directly results in the release of insulin from β cells within the islets of Langerhans, located 
in the pancreas. Insulin is the most potent anabolic hormone and once released into the 
blood stream it promotes the synthesis and storage of carbohydrates, lipids and proteins 
whilst also inhibiting their degradation and release into the circulation. Insulin stimulates the 
uptake of glucose into cells and enhances the expression and activity of glycogen synthesis 
enzymes.  Ultimately leading to a reduction in the concentration of glucose in the 
bloodstream.  
Type 1 DM (T1DM) is a disease that is caused by the autoimmune destruction of the 
insulin-producing β-cells. In T1DM patients, when blood glucose levels are increased, 
insulin is not released and the patient is subjected to chronic hyperglycaemia, unless 
otherwise treated (Atkinson, 2012). T1DM is characterized by the inflammation of the islets 
of Langerhans and β-cell damage, it is currently unclear why the autoimmune destruction is 
specific to the insulin secreting β-cells (Atkinson et al., 2011).On the other hand, Type 2 DM 
(T2DM) is due to impaired insulin release as well as insulin resistance (Kahn, Cooper & Del 
Prato, 2014). T2DM is caused by the combination of genetic and environmental factors 
which result in impaired insulin secretion and insulin resistance. Environmental factors that 
are known to contribute to T2DM include: obesity, lack of exercise, stress and aging. T2DM 
begins with insulin resistance which results in an increase in insulin secretion and glucose 
levels are maintained, this only then becomes a problem when the β-cells are no longer 
able to increase insulin secretion to overcome the ever-increasing insulin resistance. 
Therefore patients with T2DM are likely to have higher absolute insulin levels compared to a 
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healthy control, although this is still lower than necessary due to the degree of insulin 
resistance (Skyler et al., 2017).  
It is a well-established fact that DM is a major risk factor for CVD (World heart 
federation, 2017), and risk factors associated with T2DM are very similar to CVD risk 
factors. Approximately 65% of all diabetic deaths are due to CVD and the risk of 
cardiovascular mortality is 2-4 times higher in patients with DM in comparison to non-
diabetics (Deshpande, Harris-Hayes & Schootman, 2008). CVD is the most common cause 
of morbidity and mortality in diabetic patients and accelerated atherosclerosis is thought the 
be the main underlying factor that contributes to the high risk of CVD incidence (Nathan, 
1993). Diabetic angiopathy involves inflammation, atherosclerosis and thrombus formation 
all of which platelets play a vital role in. The pathogenesis and increased risk of CVD in 
diabetes cannot simply be explained by the co-existence of the classic risk factors such as 
smoking, hypertension and obesity but can be explained by an increase in platelet reactivity 
seen in patients with DM. Table 1 lists the main platelet abnormalities seen in diabetic 
patients (Natarajan, Zaman & Marshall, 2008; Papazafiropoulou, Papanas, Pappas, 




Platelet hyperreactivity is arguably an important factor promoting increased risk of CVD 
in patients with diabetes - with an increase in the number of activated circulating platelets 
leading to an enhanced likelihood of thrombus formation, occlusion, and life-threatening 
complications. It is widely accepted that diabetic platelets are hyperreactive (Vinik, Erbas, 
Park, Nolan & Pittenger, 2001), however the underlying cause/mechanism is less well 
understood. There are several theories as to what may cause this increase in platelet 




 Oxidative stress and inflammation 
 Insulin resistance and insulin deficiency 
 Metabolic abnormalities  
 
Oxidative stress and inflammation are both associated with DM and it has been 
demonstrated that they contribute to increased platelet reactivity (Calverley et al., 2003; 
Salvemini, de Nucci, Sneddon & Vane, 1989). Oxidative stress has been shown to reduce 
NO and prostacyclin production by impairing endothelial function (Schäfer & Bauersachs, 
2008).  
A few studies have suggested that loss of platelet insulin sensitivity is a cause of platelet 
hyperreactivity and demonstrate that platelet activation is antagonised by insulin 
(Westerbacka et al., 2002). Therefore, implying that in patients who have decreased insulin 
levels and increased insulin resistance, their platelets are no longer subjected to insulin-
mediated antagonism and platelet reactivity is increased. However, as previously discussed, 
patients with T2DM actually have increased actual levels of insulin in circulation and 
therefore if insulin does inhibit platelet activation this would suggest that in patients with 
T2DM platelet activity would be reduced - which is not the case. Additionally, a number of 
other studies have demonstrated that insulin does not reduce platelet function. Growth 
factors related to insulin actually increase platelet function and deletion of the insulin 
receptor in mouse platelets resulted in reduced aggregation, granule secretion and integrin 
αIIbβ3 activation (Moore et al., 2015). It has also been confirmed that there is relatively low 
insulin receptor expression on human platelets and that insulin, therefore, has a minimal 
effect on platelet function (Hunter & Hers, 2009). Therefore, concluding that a reduction in 
serum levels of insulin does not cause platelet hyperreactivity observed in diabetes.  
There are several metabolic conditions that are associated with DM including; obesity, 
dyslipidaemia and hyperglycaemia. The present study focuses on investigating the effects 
of hyperglycaemia on platelet hyperreactivity.  
Hyperglycaemia 
A blood glucose concentration of 5.5 mmol/L or lower is considered normal during 
fasting and a concentration of less than 7.8 mmol/L 2 hours post prandial is considered 
normal. Whereas a typical diabetic blood glucose concentration during fasting is > 7 mmol/l 
and > 11.1 mmol/l 2 hours post prandial (The Global Diabetes Community, 2018). 
Hyperglycaemia is the main diabetic phenotype and diabetic platelets will be exposed to 
chronic hyperglycaemia. There are many ways in which this could be the cause of platelet 
hyperreactivity in DM patients with short term glycaemic control has been shown to reduce 




There have been several studies conducted with the aim of investigating the effect of 
hyperglycaemia on platelet function, table 2 summarises a few of their findings. In general, 
studies into the effect of hyperglycaemia on platelet function seem to produce a varied 
range of results. For example, some studies show that hyperglycaemia can enhance 
platelet aggregation, but others show no effect of hyperglycaemia on platelet aggregation. 
Several studies that have shown high glucose treatment enhances platelet aggregation 
repeated their experiments in the presence of the iso-osmolar control, mannitol, instead of 
high glucose and found this showed the same effect. Therefore, any effect of 
hyperglycaemia could purely be due to an increase in osmolarity (Keating, Sobel & 
Schneider, 2003; Sudic, Razmara, Forslund, Ji, Hjemdahl & Li, 2006). On the other hand, 
studies using the same control have concluded that the effects of glucose are not due to an 
increase in osmolarity (Russo et al., 2012). Conversely, there is little variation in the 
literature regarding the ability of glucose to rescue the inhibitory effects of aspirin. The 
majority of studies dedicated to investigating this have shown that the presence of a high 
concentration of glucose results in a decrease in the inhibition of platelet aggregation 
induced by aspirin (Kobzar, Mardla & Samel, 2011; Le Guyader, Pacheco, Seaver, Davis-
Gorman, Copeland & McDonagh, 2009; Russo et al., 2012). 
Platelets express glucose transporter 1 (GLUT1) and glucose transporter 3 (GLUT3) 
(Craik, Stewart & Cheeseman, 1995) which mediate glucose entry into the platelet via 
facilitative diffusion. GLUT3 is the more abundant glucose transporter in platelets and 
approximately 85% is located on α-granule membranes and 15% is located on the platelet 
plasma membrane (Heijnen, Oorschot, Sixma, Slot & James, 1997). Uptake of glucose into 
platelets is enhanced when platelets are activated (Karpatkin, 1967). Platelet activation and 
secretion leads to the translocation of α granules to the plasma membrane which results in 
increased expression of GLUT3 at the platelet plasma membrane thereby facilitating further 
glucose uptake (Fidler et al., 2017).     
Kraakman et al proposed a slightly alternative theory which could explain the 
hyperreactivity of platelets in patients with DM (Kraakman et al., 2017). In this study 
Kraakman et al suggested that hyperglycaemia causes neutrophils in the bloodstream to 
release S100 calcium-binding protein A8/A9 which would in turn bind to the receptor for 
advanced glycation end products (RAGE) on Kupffer cells. This results in the release of 
interleukin 6 (IL-6) which causes TPO secretion from hepatocytes. Increased TPO leads to 
increased platelet production which ultimately results in greater numbers of reticulated 
platelets. They showed that reticulated platelets are more reactive than mature platelets, 
which could explain platelet hyperreactivity in diabetic patients. This is an interesting theory 




Table 2: Brief outline of some studies that have investigated the effects of glucose on platelet function  
Title  Hyperglycaemic effect reported  Reference  
High glucose levels enhance 
platelet activation: 
involvement of multiple 
mechanisms  
- Glucose increased thrombin stimulated platelet P-
selectin and fibrinogen binding  
-  L-glucose, sucrose and galactose produced similar 
enhancements as D-glucose, suggesting that elevated 






Li, 2006)  
Glucose and collagen 
regulate human platelet 
activity through aldose 
reductase induction of 
thromboxane  
- Collagen stimulated aggregation was enhanced when the 
platelets were pre-incubated with high glucose  
-  Concentration-dependent effect of glucose on collagen 
stimulated P selectin exposure  
(Tang et al., 
2011)  
Glucose impairs aspirin 
inhibition in platelets 
through a NAD(P)H oxidase 
signalling pathway  
- Glucose has no effect on ADP induced platelet 
aggregation 
-  Glucose reversed aspirin inhibition of ADP-stimulated 






Effects of increased 
concentrations of glucose 
on platelet reactivity in 
healthy subjects and in 
patients with and without 
diabetes  
- Exposure of both healthy and diabetic platelets to an 
increase in glucose resulted in an increase in P selectin 
exposure and integrin activation 
- - Same effect was seen in the presence of the 
metabolically inactive mannitol so they concluded that 
the increase in platelet reactivity was due to an increase 






platelet activation in type 2 
diabetes is resistant to 
aspirin but not to a nitric 
oxide donating agent  
- Arachidonic acid induced platelet aggregation was 
unaffected by acute hyperglycaemia  
-  P selectin expression on platelets was unaffected by 
acute hyperglycaemia 
-  Acute hyperglycaemia enhanced shear stress induced 
platelet activation and this was resistant to aspirin 
inhibition  
(Gresele et 
al., 2010)  
Short term exposure of 
platelets to glucose impairs 
inhibition of platelet 
aggregation by 
cyclooxygenase inhibitors  
- 22.4 mM glucose impaired aspirin inhibition of ADP, 
arachidonic acid, collagen and thrombin stimulated 
platelet aggregation 





High glucose inhibits the 
aspirin-induces activation 
of the nitric oxide /cGMP 
/cGMP-dependent protein 
kinase pathway and doesn’t 
affect the aspirin-induced 
inhibition of thromboxane 
synthesis in human 
platelets  
-  Platelet exposure to 25 mmol/L glucose reduced the 
ability of aspirin to inhibit platelet aggregation  
-  Glucose had no effect on the ability of aspirin to inhibit 
thromboxane synthesis  
-  Hyperglycaemia prevented the aspirin-induced 
activation of the NO/cGMP/PKG pathway 
-  No effect of the iso-osmolar mannitol was seen  
(Russo et 
al., 2012)  
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 Platelet primers 
It is well documented that increased levels of circulating primers can induce platelet 
hyperreactivity (Gresele, Falcinelli & Momi, 2008; Lupia et al., 2009; Stolla, Li, Lu & Woulfe, 
2013). A platelet primer cannot stimulate platelet aggregation by itself, but can enhance 
platelet functional responses induced by agonist (e.g. PAR1-AP, CRP-XL etc) stimulation. 
Table 3 lists the main known platelet primers (Gresele, Falcinelli & Momi, 2008). This study 
will predominantly focus on the ability of TPO to induce platelet hyperreactivity, as TPO 




TPO is a humoral growth factor that is produced by the liver and kidneys. It is removed 
from circulation when it binds to its receptor, c-Mpl, which is present on both 
megakaryocytes and platelets (Li, Xia & Kuter, 1999). Upon binding to the c-Mpl receptor on 
megakaryocytes, TPO induces proliferation and production of platelets (Fig. 3) 
(Kaushansky, 1995) . TPO is therefore of particular pharmacological interest for the 
treatment of thrombocytopenia (Kuter, 2009). In this role, TPO is well defined, however less 
is known about the ability of TPO to act directly on platelets. TPO is a known platelet primer, 
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which has been demonstrated to enhance platelet functional responses induced by platelet 
agonists (van Willigen, Gorter & Akkerman, 2000). 
 
 
Figure 3: Thrombopoietin dependent platelet production. Megakaryocytes produce platelets, 
which when initially released into the bloodstream maximally internalise TPO. As the platelets 
become more mature they become less sensitive to TPO. Mature platelets are recognised by the 
hepatic Ashwell-Morrell receptor (AMR) and are ingested by hepatocytes. The ingestion of mature 
platelets results in hepatic release of TPO into the bloodstream. TPO binds to the c-Mpl receptor on 
megakaryocytes and stimulates the production of platelets. (Grozovsky, Giannini, Falet & 
Hoffmeister, 2015; Natarajan, Zaman & Marshall, 2008).  
It has also been shown that TPO can enhance firm platelet adhesion to vWF, indicating 
that TPO might play an important role in thrombus formation (Van Os et al., 2003). TPO has 
been shown to enhance platelet functional responses via a phosphoinositide 3-kinase 
(PI3K)-dependent mechanism (Pasquet et al., 2000).  
Serum levels of platelet primers such as tissue factor, insulin growth factor-1 (IGF-1) 
and TPO have been shown to be enhanced in patients with DM (Gerrits, Koekman, van 
Haeften & Akkerman, 2010; Grove, Hvas, Mortensen, Larsen & Kristensen, 2011; Stolla, Li, 
Lu & Woulfe, 2013). Grove et al (Grove, Hvas, Mortensen, Larsen & Kristensen, 2011) 
demonstrated that TPO levels in the blood are significantly higher in patients with diabetes 
compared to healthy controls. Lupia et al (Lupia et al., 2006) investigated the potential role 
of elevated levels of TPO in platelet activation during UA. This study showed that patients 
with UA had significantly higher TPO serum levels in comparison to healthy controls and UA 
patients platelets expressed elevated numbers of the TPO receptor c-Mpl. Lupia et al (Lupia 
et al., 2006) suggest that TPO may increase platelet activation in patients suffering from 
acute angina and ultimately contribute to the pathogenesis of acute coronary syndrome. An 
aim of this study was to investigate whether TPO plays a role in promoting platelet 
hyperreactivity in diabetic platelets and whether platelet reactivity could be further enhanced 





The symptoms associated with DM put patients at high risk of long-term macro- and 
micro-vascular complications, which if not treated, could lead to death. There are several 
different treatment options available depending on the type of diabetes and the individual. 
For patients diagnosed with T1DM treatment is focused on increasing insulin levels usually 
via a self-administered insulin injection. In patients diagnosed with T2DM, because they 
have a reduced response to insulin, the therapeutic focus is on preventing complications 
caused by hyperglycaemia. The main classes of oral anti-diabetic medication used to treat 
T2DM include; sulfonylureas, biguanides, thiazolidinediones, meglitinide, dipeptidyl 
peptidase 4 (DPP-A) inhibitors, sodium-glucose cotransporter inhibitors and α-glucosidase 
inhibitors (Chaudhury et al., 2017).  
As well as the 'normal' symptoms of diabetes the increased risk of CVD also needs to be 
treated. CVD risk can be greatly reduced with anti-platelet therapy in non-diabetic patients. 
However, anti-platelet therapies are generally less efficacious in diabetic patients (Angiolillo, 
2009). Patients who are resistant to antiplatelet therapies have been shown to have 
hyperreactive platelets (Angiolillo et al., 2005; Dichiara et al., 2007; Macchi et al., 2002). It is 
possible that the resistance to antiplatelet treatment shown by diabetics is due to the 
hyperreactive platelet phenotype. Therefore, it is imperative that an alternative antiplatelet 
therapy for patients with DM is investigated. 
Coincidently, a few anti-diabetic treatments, the oral hypoglycaemic agents such as the 
biguanides, sulfonylureas and glitazones in particular, also show antiplatelet properties 
(Ishizuka et al., 1998; Papazafiropoulou, Papanas, Pappas, Maltezos & Mikhailidis, 2015; 
Xiao et al., 2015). Numerous studies have investigated the effects of diabetes treatment on 
platelet function, but the results have been variable. This study will focus on the effects of 
metformin and rosiglitazone on platelet function. 
Metformin 
Metformin is an oral anti-diabetic that helps to control blood sugar levels and is the first 
line medication for the treatment of T2DM. Metformin is an example of a biguanide and it 
works by activating adenosine monophosphate-activated protein kinase in the liver, which in 
turn causes hepatic uptake of glucose and inhibition of gluconeogenesis.  
It has been reported that metformin reduces mortality and diabetes-associated 
thrombotic complications (Lu et al., 2014; Roussel et al., 2010). There are a few studies 
investigating the effects of metformin therapy on platelet function. Xin et al (Xin et al., 2016) 
showed that metformin inhibits platelet activation both in vivo and in vitro. They suggest that 
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metformin does this by lowering extracellular mitochondrial DNA release which can 
supposedly act as an agonist to induce platelet activation and thrombosis. Metformin has 
also been shown to reduce oxidative stress and limit platelet activation in a study with newly 
diagnosed T2DM patients (Formoso et al., 2008). However, it has been suggested that any 
effect metformin has on platelet function is an indirect effect, based on the ability of 
metformin to reduce glucose levels rather than any direct effect on platelets (Collier, 
Watson, Patrick, Ludlam & Clarke, 1989).  
Metformin is a cationic drug and therefore depends on transporters such as; organic 
cation transporters (OCTs) and multidrug and toxin extruders (MATEs) for its 
pharmacokinetic movement across the cell membrane (Pakkir Maideen, Jumale & 
Balasubramaniam, 2017). OCT proteins are members of the solute carrier family, subfamily 
22 (SLC22). According to the human proteome map both SLC22A1 (OCT1) and SLC22A18 
are present in platelets (Fig. 4). It is therefore reasonable to suggest that metformin may 
well be capable of getting across the platelet cell membrane and having a direct effect on 
platelet function. Therefore, further investigation into the mechanism of action of metformin 
and its ability to affect platelet function is required.  
 
Figure 4: Human proteome map of solute carrier family, subfamily 22. The human proteome 
map, analysed by total proteome mass spectrometry (reference), was queried for the SLC22A protein 
family and the relative abundance of each protein is shown in a heat map. White represents little or 






Rosiglitazone is an example of a thiazolidinedione and acts as an insulin sensitizer by 
improving insulin action. Following a meta-analysis published in 2007 that linked 
rosiglitazone use to an increased risk of heart attack rosiglitazone has been withdrawn from 
the European market but it remains available in the US (Nissen & Wolski, 2007). 
Rosiglitazone is an agonist at the peroxisome proliferator-activated receptors (PPAR), a 
group of receptors that belong to the nuclear hormone receptor superfamily of ligand-
activated transcription factors, with the greatest specificity for PPARγ. Upon activation, 
PPARγ facilitates increased glucose uptake in numerous tissues including adipose, muscle 
and liver. Platelets are known to express PPARγ (Akbiyik, Ray, Gettings, Blumberg, Francis 
& Phipps, 2004) and both natural and synthetic PPARγ ligands have been shown to inhibit 
platelet function, thrombosis and haemostasis (Unsworth, Flora & Gibbins, 2018). Sidhu et 
al showed that rosiglitazone reduces platelet activity in non-diabetic patients with coronary 
artery disease (Sidhu, Cowan & Kaski, 2004) and Khanolkar et al showed that rosiglitazone 
further reduced platelet aggregation and oxidative stress in patients with T2 DM (Khanolkar 
et al., 2008).  
A recent study has shown that PPAR ligands, such as rosiglitazone, modulate the 
activity of the GPVI collagen receptor-stimulated signalling pathway. Which in turn results in 
inhibited platelet activation, aggregation and thrombus formation (Moraes et al., 2010). It 
has also been suggested that the anti-platelet effects of rosiglitazone are AMP-activated 
protein kinase (AMPK) mediated (Liu, Park, Chang, Huh, Lee & Lee, 2016). AMPK is an 
enzyme that is known to play a role in cellular energy homeostasis. Liu et al found that 
rosiglitazone stimulated both AMPK and PPARγ in platelets. And although stimulation of 
either lead to reduced platelet aggregation the efficacy attributable to AMPK activation was 
much greater than that caused by PPARγ stimulation (Liu, Park, Chang, Huh, Lee & Lee, 
2016).  
Aims 
Platelet hyperreactivity in diabetes is likely to lead to the acceleration of a cardiac event 
and it is important that the mechanisms underlying such hyperreactivity are investigated. 
This project has four main aims. Firstly, to investigate the effects of hyperglycaemia on 
platelet function, including aggregation, PS exposure, mitochondrial membrane potential, 
ROS generation and calcium signalling. Secondly, to extend previous studies by showing 
the effects of the platelet primer, TPO, on aggregation, PS exposure, ROS generation and 
mitochondrial membrane potential. Thirdly, to determine whether hyperglycaemia affects the 
ability of TPO to enhance platelet function. And finally, the fourth aim was to study whether 
anti-diabetic treatments are able to reverse the hyperreactive qualities induced by TPO 
and/or hyperglycaemia.  
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Materials and Methods  
Materials 
Agonists, Antagonists and Inhibitors  
Protease-activated receptor 1 (PAR-1)-activating peptide (SFLLRN-NH2) was from 
Bachem (Switzerland). Crosslinked collagen-related peptide (CRP-XL) was from Richard 
Farndale (University of Cambridge). Human recombinant TPO, aspirin, ARC66096 
tetrasodium salt, rosiglitazone and metformin were from Bio-techne (Abingdon, UK). D-
glucose was from ThermoFisher Scientific (Loughborough, UK). Insulin-like growth factor-1 
(IGF-1) was from Immunological and Biochemical Test Systems (Binzwangen, Germany). 
Apyrase, prostaglandin E1 (PGE1), indomethacin, mannitol and thrombin were all sourced 
from Sigma Aldrich (Poole, UK).  
Flow cytometry and calcium assay antibodies and dyes  
FITC-conjugated PAC-1 and PE-conjugated CD62P antibodies were from BD 
Biosciences (Berkshire, UK). Annexin V-Alexa Fluor 488 conjugate, Tetramethylrhodamine 
(TMRM), CM-H2DCFDA (general oxidative stress indicator) and Fura-2 AM cell permanent 
calcium indicator were from Thermo Fisher Scientific (Loughborough, UK). 
Buffers and Solutions 
Buffer/Solution Composition 
ACD 85 mM trisodium citrate dihydrate, 71 mM citric 
acid, 111 mM D-glucose 
HEPES-Tyrode (pH 7.2) 10 mM HEPES, 145 mM sodium chloride, 3 mM 
potassium chloride, 0.5 mM sodium dihydrogen 
phosphate, 1 mM magnesium sulphate 7-hydrate 
Anticoagulant 4 % trisodium citrate dihydrate dissolved in purified 
H2O 
EGTA 100 mM EGTA, 10 mM HEPES 
Tris, pH 7.4 500 mM Tris Base 
Triton 20 % triton dissolved in H2O 
Trisodium citrate Dissolved in Mili-Q water to 4% w/v. 
 





 Platelet Preparation: 
Venous blood was obtained from healthy, male and female, drug-free, human volunteers 
in accordance with the local research ethics committee at the University of Bristol. A signed 
consent form in accordance with the Declaration of Helsinki was obtained from each 
volunteer. Blood was anticoagulated with 4% sodium citrate (1:9) and acidified with acid 
citrate dextrose (1:7, 25 μg/mL sodium citrate, 20 μg/mL glucose, 15 μg/mL citric acid). 
Platelet-rich plasma (PRP) was obtained by centrifugation at 180 g for 17 minutes. 10 μM 
indomethacin and 0.02 U/ml apyrase or 140nM PGE1and 0.02 U/mL apyrase were added to 
PRP and centrifuged at 520 g for 10 minutes. Platelets were then resuspended at 4x108 
cells/mL in modified HEPES-Tyrode’s (HT) buffer (145 mM NaCl, 3 mM KCl, 0.5 mM 
Na2HPO4, 1 mM 5 MgSO4.7H2O, 10 mM HEPES, pH 7.2, 0.1% (w/v) D-glucose, 10 μM 
indomethacin / 140nM prostaglandin E1 and 0.02 U/ml apyrase) and rested for 30 minutes 
at 30°C. All platelet counts were performed using a Z1 Coulter Particle Counter (Beckham 
Coulter Inc, High Wycombe, UK). Platelets used in all experiments were suspended in HT 
containing 5.5 mM glucose unless otherwise stated.  
 Aggregation 
Aggregation was induced by PAR1-AP or CRP-XL in washed human platelets (2x108 
cells/mL) and monitored for 5 minutes at 37°C under continuous stirring conditions. Platelets 
were pre-incubated with either vehicle (HT), glucose or mannitol for 10 minutes prior to 
agonist stimulation. TPO / IGF-1 were pre-incubated with platelets for 5 minutes before 
agonist stimulation. Platelets were incubated with metformin for 20 minutes (acute) or 5 
hours (chronic) and rosiglitazone for 10 minutes prior to stimulation. All platelet aggregation 
studies were conducted using a Chrono-log 490 aggregometer (Labmedics, Oxfordshire, 
UK). Changes in light-transmission were recorded for 5 minutes, from the addition of 
agonist, using Aggrolink Version 4 software.  
Flow cytometry 
PS exposure 
Annexin V, Alexa Fluor 488 conjugate was used to detect surface PS exposure. Washed 
human platelets were diluted to 2x107 cells/mL using modified HT (supplemented with 1.2 
mM Ca2+). To each well of a 96-well plate 1 μL of Annexin V, 2.5 μL of CRP-XL (0.3-3 
μg/mL) and 2.5 μL of Thrombin (0.5-2 M)  were added. The diluted platelets were incubated 
with vehicle (HT) or glucose (10 mins, RT) and vehicle (HT) or rh TPO (5 mins, RT). For 
experiments including rosiglitazone, platelets were treated with 100 μM rosiglitazone for 10 
minutes prior to stimulation. 44 μL of platelets were then added to each well. After 5 minutes 
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(or 10 minutes depending on desired stimulation time) 200 μL of HT (+ 2mM CaCl2) was 
added to each well in order to quench the reaction. The plate was then read on a BD Acuri 
C6 Plus (BD Biosciences, 5000 platelet sample events were recorded, and data was 
analysed using Flow Version 1.6 software.  
Mitochondrial Membrane Depolarisation with TMRM 
Tetramethylrhodamine (TMRM) was used as a mitochondrial membrane potential 
indicator. Washed human platelets (2x108 cells/mL) suspended in modified HT in the 
presence of CaCl2 ( 1.2 mM ) were dye loaded with 0.5 μM TMRM (30 mins, RT, in the 
dark). Platelets were then diluted (2x107 cells/mL) in modified HT  and incubated with either 
vehicle (HT) or glucose (10 mins, RT) and vehicle (HT) or TPO (5 mins, RT). For 
experiments including rosiglitazone and metformin, platelets were treated with 100 μM 
rosiglitazone (10 minutes, 30⁰C) or 40 μM metformin (20 minutes, 30°C) prior to stimulation. 
And then stimulated with both CRP-XL (5 μg/mL) and Thrombin (1U/mL) for 5 minutes. 50 
μL of platelets were then added to 150 μL of modified HT in a 96-well plate to quench the 
reaction. The plate was then read on a BD Acuri C6 Plus. 10,000 platelet sample events 
were recorded, and data was analysed using Flow Version 1.6 software.    
Reactive Oxygen Species Generation with CM-H2DCFDA 
CM-H2DCFDA was used as an indicator of ROS generation. Washed human platelets 
(2x108 cells/mL) were loaded with CM-H2DCFDA (5 μM, 30mins, 37°C, in the dark) in 
modified HT in the presence of CaCl2 (1.2 mM). Platelets were then diluted (2x10
7 cells/mL) 
in modified HT in the presence of CaCl2 (1.2 mM) and loaded with CM-H2DCFDA (5 μM ) 
prior to incubation with 5.5mM glucose or 25 mM glucose (10 mins, 37 °C) and vehicle (HT) 
or 100 ng/mL TPO (5 mins, 37 °C). For experiments including rosiglitazone and metformin, 
platelets were treated with 100 μM rosiglitazone (10 minutes, 30⁰C) or 40 μM metformin (20 
minutes, 30°C) prior to stimulation. Samples were then stimulated with 5 μg/mL CRP-XL 
and increasing concentrations (0.01 - 3 U/mL) of thrombin (5 mins, 37 °C) and the reaction 
was quenched using dye-loaded HT. Samples were immediately read on a BD Acuri C6 
Plus. 10, 000 platelet sample events were recorded, and data was analysed using Flow 
Version 1.6 software. 
P-selectin Exposure and Integrin Activation 
Platelet integrin IIb3 activation and -granule secretion was monitored by flow 
cytometry using FITC-conjugated PAC1 antibody (used to assess integrin αIIbβ3 activation) 
and PE conjugated CD62P (used to quantify P-selectin exposure as an indicator of α 
granule secretion). Platelets (2x107 cells/mL) suspended in modified HT were pre-incubated 
with either vehicle (H2O) or 40 μM metformin (20 minutes, 30°C) or vehicle (DMSO or 100 
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μM rosiglitazone (10 minutes, 30°C ). Platelets were then stimulated with 5 μM PAR1-AP or 
5 μg/mL CRP-XL for 10 minutes in the presence of FITC PAC1 and PE CD62P. Addition of 
2% PFA was used to fix the reaction. Samples were analysed on a BD Accuri C6 Plus (BD 
Bioscience) using FACS Diva software (BD Bioscience, Oxford, UK).  
 Calcium signalling 
PRP, prepared as previously stated, was loaded with 4 μM Fura2 AM (1 hr, 30°C). 
Platelets were collected by centrifugation at 520 g for 10 minutes and re-suspended in 
modified HT at 2x108 cells/mL and rested for 30 minutes to allow complete de-esterification 
of intracellular AM esters (the de-esterification process liberates the Ca2+-sensitive 
indicator). Fluorescence was monitored and recorded at 37°C using Tecan infinite M200 Pro 
multimode reader (Tecan Trading AG, Switzerland) and excitation at 340 nm and 380 nm 
before and after addition of agonist. 20% Triton was added to each well to cause cells to 
lyse and maximum Ca2+ release, followed by addition of 0.5 M EGTA and 0.5 M TRIS at pH 
7.4 used to chelate divalent cations and provide a minimum Ca2+ release recording. 
Changes in cytosolic [Ca2+] were monitored using the 340/380 nm fluorescence ratio.  
 Data analysis 
All data were analysed and curves fitted using GraphPad Prism 7.02 software 
(GraphPad Software, San Diego, CA, USA). Data are presented as the mean ± standard 
error of the mean (SEM) of a minimum of three independent experiments. Data that has 
been presented with statistical analysis were tested using either a two-tailed paired 
Student’s t-test, a two-way ANOVA with a Bonferroni multiple comparison post hoc test or a 
one-way ANOVA with a Dunnett's multiple comparisons post hoc test. A students T-test was 
used to test the hypothesis: there is a difference between two sample means. A one-way 
ANOVA with Dunnett's multiple comparison post hoc test was used to compare each of a 
number of treatments to a single control group. And a two-way ANOVA with Bonferroni 
multiple comparison post hoc was used to compare concentration response curves. For 
some of the statistical analysis I had to assume the data was normally distributed.  A P 
value of less than 0.05 was considered statistically significant: * P<0.05, **P<0.01, 









Acute hyperglycaemia does not alter platelet aggregation 
In order to determine whether hyperglycaemia can contribute to platelet hyperreactivity 
in diabetics, the effect of high/increased glucose concentrations on platelets from healthy 
volunteers was investigated. Washed human platelets in the presence of either 5.5 mM or 
25 mM glucose or 5.5 mM glucose + 19.5 mM mannitol were stimulated with either PAR1-
AP or CRP-XL and aggregation continuously monitored (Fig. 5A-D). Mannitol was used as 
an osmotic control. Mannitol is a sugar alcohol that is not transported into platelets and is 
commonly used as an osmotic control for high glucose treatment. Pre-incubation of platelets 
for 10 minutes with 25 mM glucose was observed to not significantly alter platelet 
aggregation induced by CRP-XL or PAR1-AP compared to 5.5 mM glucose (Fig.5A-D). As 
the effect of glucose may be time dependent, the experiment was repeated using various 
incubation times with glucose. Platelets were incubated with high glucose or mannitol for 10, 
20, 30, 60 and 90 minutes and aggregation continuously monitored (Fig.5E). Extending the 
time platelets were incubated with 25 mM glucose also failed to significantly alter platelet 
aggregation. Concentration-response curves can be bell shaped, with molecules inducing 
differing effects at low and high concentrations. Therefore, to investigate whether a 
concentration of glucose > 5.5 mM but < 25 mM could alter platelet function, aggregation 
was recorded using platelets that had been preincubated with a range of glucose 
concentrations (Fig. 5F). However, none of the glucose concentrations tested significantly 














Figure 5: The effect of D-glucose on platelet aggregation. Washed human platelets (2 × 10
8
/mL) 
were incubated with 5.5 mM glucose, 25 mM glucose or 5.5 mM glucose + 19.5 mM mannitol for 10 
minutes before stimulation. (A) Platelets were stimulated with increasing concentrations of CRP-XL 
(0.1- 3 μg/mL) and maximum aggregation was recorded. NS. N=8. A two-way ANOVA with a 
Bonferroni multiple comparisons post-hoc test was performed.  (B) Representative aggregation trace. 
(C) Platelets were stimulated with increasing concentrations of PAR1-AP (0.5-2 μM) and maximum 
aggregation was recorded. NS. N=3. A two-way ANOVA with a Bonferroni multiple comparisons post-
hoc test was performed (D) Representative aggregation trace (E) A bar chart showing the effect of 
platelet incubation time with glucose/ mannitol on the effects of 25 mM glucose and 19.5 mM 
mannitol on CRP-XL (1 μg/mL) platelet aggregation compared to 5.5 mM glucose. NS. N=4. A two-
way ANOVA test was performed. (F) A representative aggregation trace showing the effects of 
different glucose concentrations on maximum aggregation. 
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TPO-mediated enhancement of aggregation is unaltered by hyperglycaemia 
TPO is a known platelet primer and has been shown to increase platelet 
aggregation in several publications (Blair, Moore & Hers, 2015). Initially, my aim was 
to reproduce previous findings by treating platelets with TPO (100 ng/mL, 5 min) 
prior to platelet stimulation with CRP-XL and demonstrating whether platelet 
aggregation was enhanced in the presence of TPO. My data confirms that 100 
ng/mL TPO significantly enhances CRP-XL mediated platelet aggregation (Fig 6A-
B). TPO alone did not induce platelet aggregation (data not shown). IGF-1 is also a 
known platelet primer that has been shown to increase platelet aggregation. Figure 
6C shows that IGF-1 also significantly enhanced CRP-XL stimulated platelet 
aggregation. I was also interested in whether higher concentrations of glucose could 
alter the effect of TPO on enhancing platelet function. Therefore, platelets were pre-
incubated with 5.5 or 25 mM glucose in the presence or absence of 100 ng/mL TPO 
before stimulation with CRP-XL. Incubation of platelets with 25 mM glucose did not 




Figure 6: The effect of platelet primers and glucose on aggregation. (A-C) Washed human 
platelets (2x10
8 
cells/ mL) were incubated with 100 ng/mL TPO, 100 nM IGF-1 or vehicle (HT) for 5 
minutes prior to stimulation with a sub threshold concentration of CRP-XL (0.7-1 μg/mL). (A) 
Concentration-response curve showing the effects of TPO on maximum platelet aggregation. N=3. (B 
and C) Representative aggregation traces. (D-E) Washed human platelets (2x10
8
 cells/ mL) were 
incubated with normal (5.5 mM) or high (25 mM) glucose for 10 minutes. Platelets were also treated 
with either vehicle (HT) or 100 ng/mL TPO for 5 minutes prior to stimulation. (D) Concentration-
response curve showing the effect of TPO, glucose and TPO+glucose on aggregation. N=3. NS. (E) 
Representative aggregation trace. Two-way ANOVA with a Bonferroni multiple comparisons post-hoc 
test was performed. 
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TPO enhances platelet PS exposure 
PS exposure is another important marker of platelet activation as it is fundamental for 
thrombin generation and therefore plays a key role in the blood coagulation process. It is 
important to also consider the effect glucose and TPO on this aspect of platelet function. In 
resting platelets PS is found on the inner leaflet of the plasma membrane but under certain 
conditions (dual stimulation, apoptosis) it is flipped to the outer leaflet by an enzyme called 
scramblase and can be probed using the PS-binding protein annexin V. Initially, 
experiments were set up to determine the optimum conditions for TPO to enhance PS 
exposure (Fig. 7A-B). Some preliminary experiments, investigating the effect of TPO on PS 
exposure when platelets were stimulated with both CRP-XL and thrombin for a range of 
stimulation times (2 - 30 minutes), indicated that TPO had its greatest effect at the lower 
stimulation time points (data not shown). Therefore the effect of TPO on PS exposure when 
platelets were stimulated for 5 and 10 minutes was investigated in more detail. Pre-
treatment of platelets with TPO for 5 minutes followed by stimulation with agonist (CRP-XL 
and thrombin) for 10 minutes demonstrated that TPO under these conditions did not 
significantly alter PS exposure (Fig. 7A). However, platelets pre-treated with TPO for 5 
minutes followed by stimulation with agonist (CRP-XL and thrombin) for 5 minutes 












Figure 7: TPO enhances agonist-mediated PS exposure. Washed human platelets (2x10
7
 
cells/mL) were treated with either 100 ng/mL TPO or vehicle (HT) for 5 minutes prior to stimulation 
with 5 μg/mL CRP-XL and increasing concentrations of thrombin (0.01 - 1 U/mL). Percentage of 
platelets exposing PS was recorded as a result of CRP-XL and thrombin stimulation for (A) 10 
minutes (NS) and (B) 5 minutes. N=3. Two-way analysis of variance with Bonferroni multiple 













Hyperglycaemia enhances platelet PS exposure 
Next, the effect of hyperglycaemia and the combined effect of hyperglycaemia and TPO 
on PS exposure was assessed. Figure 8A shows that platelets pre-treated with 25 mM 
glucose for 10 minutes prior to agonist stimulation exposed significantly more PS compared 
to platelets pre-treated with the normal 5.5 mM glucose.  The combined pre-treatment of 
high glucose and TPO (Fig. 8C) had no additive effect compared to glucose and TPO alone 
(Fig. 8A and B, respectively). I then tested the effect of a range of glucose concentrations 
(5.5, 10, 15, 20 and 25 mM) on agonist (CRP-XL and thrombin) mediated PS exposure. 
Figure 8D shows the EC50 values of the concentration response curves decreases as the 
concentration of glucose increases. This shows that glucose concentration dependently 

















Figure 8: Glucose enhances agonist-mediated PS exposure. (A) Washed human platelets (2x10
8
 
cells/mL) were incubated with 5.5 mM glucose or 25 mM glucose for 10 minutes and 100 ng/mL TPO 
or vehicle (HT) for 5 minutes prior to stimulation with 5 μg/mL CRP-XL and increasing concentrations 
of thrombin (0.01-1 U/mL) and PS exposure was recorded. N=6. (B) Platelets, incubated with various 
concentrations of glucose for 10 minutes, were stimulated with 5 μg/mL CRP-XL and increasing 
concentrations of thrombin (0.01-1 U/mL) for 5 minutes and PS exposure was recorded. 
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TPO and hyperglycaemia alter agonist-mediated changes in ROS generation and 
mitochondrial membrane potential  
As previously mentioned, both platelet ROS generation and mitochondrial membrane 
depolarisation have been linked to an increase in PS exposure. I therefore explored the 
effect of TPO and hyperglycaemia on ROS generation and mitochondrial membrane 
depolarisation in order to validate the observed effect both TPO and glucose had on PS 
exposure. Initially, I investigated the effect of TPO and high glucose on the ability of 
platelets to produce ROS using the CM-DCFDA dye. Non-fluorescent CM-H2DCFDA 
passively diffuses into platelets and upon oxidation by ROS it becomes highly fluorescent 
and this fluorescence can be recorded using a flow cytometer. Figure 9A shows that 
platelets pre-treated with 100 ng/mL TPO for 5 minutes generated significantly more ROS 
when compared to platelets pre-treated with vehicle. Interestingly, platelets pre-incubated 
with high glucose for 10 minutes generated the same amount of ROS as platelets pre-
incubated with normal glucose (Fig. 9B). And figure 9C shows that hyperglycaemia does not 
affect the ability of TPO to enhance platelet ROS generation. 
I then used TMRM to detect any change in agonist-mediated mitochondrial membrane 
potential due to the presence of TPO or high glucose. TMRM is a cell-permeable dye that 
accumulates in active mitochondria. The fluorescent signal that TMRM produces can be 
directly related to a change in mitochondrial membrane potential (ΔΨm); upon membrane 
depolarisation TMRM leaks from within the mitochondria leading to a reduction in the 
intensity of the fluorescence. The TMRM signal can be detected and recorded using flow 
cytometry. Figure 9D shows the effect of platelet pre-treatment with TPO, 25 mM glucose 
and TPO + 25 mM glucose on stimulated platelet mitochondrial membrane potential 
compared to platelets pre-treated with 5.5 mM glucose. In accordance with their effect on 
platelet PS exposure both TPO and hyperglycaemia enhance mitochondrial membrane 
depolarisation but there is no additive effect when platelets are pre-treated with both 25 mM 




Figure 9: The effect of glucose and TPO on ROS generation and ΔΨm. Washed human platelets 
(2x10
7
 cells/mL) were incubated with 5.5 mM glucose or 25 mM glucose for 10 minutes and vehicle 
(HT) or 100 ng/mL TPO for 5 minutes prior to stimulation with 5 μg/mL CRP-XL and increasing 
concentration of thrombin (0.01-3 U/mL). (A) A concentration response curve showing the effects of 
hyperglycaemia, TPO, and hyperglycaemia  and TPO on mean CM-DCFDA fluorescence.  N=5. (D) 
The effects of 10 minute incubation with 25 mM glucose or 5.5 mM glucose and 5 minute treatment 
with 100 ng/mL TPO or vehicle (HT) prior to stimulation with 5 μg/mL CRP-XL and 1 U/mL thrombin 
on washed human platelets (2x10
7
 cells/mL) on mitochondrial membrane potential were recorded as 
the median TMRM fluorescence. N=8. One-way ANOVA with a Dunnett’s post hoc test was 
performed.   
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Hyperglycaemia reduces agonist-mediated increases in intracellular calcium  
Another mechanism which has been shown to be involved in enhanced PS exposure is 
an increase in calcium mobilisation. I therefore also investigated the effects of 100 ng/mL 
TPO and 25 mM glucose on platelet calcium mobilisation using Fura-2 AM. Fura-2 AM is a 
membrane-permeable calcium indicator and once inside the platelet and bound to Ca2+ it 
fluoresces. Intracellular calcium concentrations in washed platelets were increased following 
stimulation with 5 μg/mL CRP-XL and increasing concentrations of thrombin (0.01 - 3 U/mL) 
(Fig. 10). Pre-treating the platelets with TPO for 5 minutes prior to stimulation did not alter 
calcium mobilisation compared to vehicle (Fig. 10A-B). In contrast, when the platelets were 
pre-incubated with 25 mM glucose for 10 minutes this led to a significant decrease in 
calcium signalling (Fig. 10C-D), which was reversed in the presence of TPO (Fig. 10E-F). 
This experiment was repeated with the osmotic control, mannitol, to ensure that the 
reduction in calcium signalling seen with high glucose wasn't due to an increase in 
osmolarity leading to Fura-2 AM dye leaking out of the cell. Figure 10G and 10H shows that 
treating washed human platelets with 19.5 mM mannitol had no effect on platelet calcium 
signalling in comparison to vehicle. Together, these results show that glucose significantly 















Figure 10: The effect of glucose and TPO on intracellular calcium signalling.  Washed 
human platelets were incubated with normal glucose, high glucose or mannitol for 10 minutes and 
vehicle (HT) or 100 ng/mL TPO for 5 minutes prior to stimulation with 5 μg/mL CRP-XL and 
increasing concentrations of thrombin. (A-D) Dose-response curves, represented as area under the 
curve (AUC), showing the effects of 25 mM glucose, 100 ng/mL TPO, 25 mM glucose + 100 ng/mL 
TPO and 5.5 mM glucose + 19.5 mM mannitol, respectively, on calcium mobilisation compared to 
vehicle. N=6. A two-way ANOVA with Bonferroni post hoc test was performed. 
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Inhibition of platelet function by aspirin is not altered by the presence of 
glucose 
Aspirin is a “gold-standard” anti-platelet drug and has been shown to decrease 
platelet function. It has been suggested that high blood glucose levels can reverse the 
inhibition of platelet function induced by aspirin (aspirin-resistance) (Kobzar, Mardla & 
Samel, 2011). Treatment of platelets with 30 mM aspirin for 10 minutes significantly 
reduces CRP-XL stimulated aggregation (Fig.11A), whereas aspirin had no significant 
effect on PAR1-AP stimulated aggregation (Fig. 11B). Incubating platelets in the 
presence of 25 mM glucose was observed to reduce the effect of aspirin on CRP-
mediated aggregation, however this reduction did not reach significance and was 
highly variable between donors (Fig.11A). As previously mentioned, hyperglycaemia 
has no effect on aggregation but I have shown that it is able to enhance PS exposure. I 
therefore decided to investigate the effect of aspirin on PS exposure and whether or 
not the presence of a high concentration of glucose would be able to reverse any effect 
of aspirin.  Interestingly, platelet treatment with aspirin had no effect on platelet PS 
exposure (Fig.11C). P2Y12 blockers are anti-platelet drugs that are frequently used in 
the clinic. ARC is a P2Y12 antagonist that is able to reduce PS exposure (Fig. 11C), 
however, this inhibition could not be rescued by pre-treatment with TPO, 25 mM 






Figure 11: Hyperglycaemia has no effect on the inhibition of platelet function by aspirin. 
Platelets treated with 30 mM aspirin for 10 minutes showed reduced aggregation and the 
effects of high glucose and mannitol on this affect were recorded in response to (A) 1.5 μg/Ml 
CRP-XL stimulation. N=5. And (B) 1 μM PAR1-AP stimulation. N=2. (C) A bar chart showing 
the effect of 25 mM glucose, 100 ng/mL TPO and 25 mM glucose+100ng/mL TPO on the effect 
of aspirin and ARC treatment on platelet PS exposure. N=6. 
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The anti-diabetic therapy metformin does not alter platelet function. 
Metformin is the most commonly prescribed anti-diabetic treatment and it has been 
suggested that metformin can also act as an anti-platelet therapy (Xin et al., 2016). 
Initially, I investigated the effects of 40 μM metformin on CRP-XL and PAR1-AP 
stimulated platelet aggregation. In T2DM patient treated with metformin, systemic 
plasma concentration of metformin is likely to be 10 - 40 μM (He & Wondisford, 2015). 
Therefore, for these experiments I chose to use a final metformin concentration of 40 
μM as this represents a therapeutic concentration found in patients with T2DM. 
Washed human platelets (2x108 cells/mL) were incubated with metformin for 20 
minutes prior to stimulation and aggregation was monitored and maximum aggregation 
reached was recorded. Metformin was observed to reduce platelet aggregation 
however this did not reach significance (Fig. 12A, C). Chronic incubation of platelet 
with metformin (5 hours in platelet-rich plasma) was also observed to reduce 
aggregation, but again this did not reach significance (Fig. 12B, D). Furthermore, 
treatment with metformin had no effect on CRP-XL or PAR1-AP mediated platelet 
integrin αIIbβ3 activation and p-selectin expression compared to agonist alone (Fig.12 





Figure 12: The effect of Metformin on platelet priming and function. (A+C) Washed human 
platelets (2x10
8
 cells/mL) were incubated with 40 μM metformin or vehicle (DMSO) for 20 
minutes (acute) prior to stimulation with either PAR1-AP or CRP-XL and the maximum 
aggregation reached over a 5 minute stimulation was recorded.  N=3. Paired students t-test 
was performed (B+D) PRP was incubated with 40 μM metformin for 5 hours (chronic) prior to 
PAR1-AP or CRP-XL stimulation, maximum aggregation was recorded. A paired students t-test 
was performed. The effect of acute metformin treatment on washed human platelets (2x10
7 
cells/mL) (E) alpha granule secretion and (F) integrin (αIIbβ3) activation was recorded over a 10 
minute stimulation period with either 5 μM PAR1-AP or 5 μg/mL CRP-XL. N=3.  
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 The anti-diabetic therapy rosiglitazone inhibits platelet aggregation but 
enhances ROS generation and PS exposure.  
Rosiglitazone is another anti-diabetic drug that has been suggested to have anti-
platelet properties (Liu, Park, Chang, Huh, Lee & Lee, 2016) and to investigate this 
further, the effect of 100 μM rosiglitazone on CRP-XL and PAR1-AP stimulated platelet 
aggregation was evaluated. Figure 13 A,B,D and E shows that platelet pre-treatment 
with rosiglitazone for 10 minutes prior to stimulation results in a statistically significant 
reduction in both CRP-XL and PAR1-AP stimulated maximum aggregation. Figure 13C 
and 13F shows that 100 ng/mL TPO is unable to rescue the inhibitory effects of 
rosiglitazone on both CRP-XL and PAR1-AP stimulated platelet aggregation. Due to 
the significant effect of rosiglitazone on platelet aggregation, I aimed to further 
investigate the effects of rosiglitazone on platelet function. Figure 14 shows that pre-
treatment with rosiglitazone for 10 minutes prior to stimulation slightly reduced both 
CRP-XL and PAR1-AP stimulated platelet integrin αIIbβ3 activation and P-selectin 
expression in comparison to vehicle but this did not reach significance. 
Next, I studied the effect of rosiglitazone on PS exposure and, unexpectedly, I 
found that platelets treated with rosiglitazone exposed significantly more PS when 
stimulated with CRP-XL and thrombin for 5 minutes compared to vehicle. Pre-
treatment with either 100 ng/mL TPO or 25 mM glucose as well as 100 μM 
rosiglitazone had no additive or inhibitory effect on the enhancement of PS exposure 
seen with rosiglitazone alone (Fig. 15A+B). I subsequently investigated the effect of 
rosiglitazone on platelet ROS generation and mitochondrial membrane potential. As 
treatment with rosiglitazone resulted in an increase in PS exposure, I hypothesised that 
it will also cause an increase in ROS generation and mitochondrial membrane 
depolarisation. As predicted figure 15C shows that pre-treatment with rosiglitazone 
caused an increase in platelet ROS generation compared to vehicle but not to the 
same extent as TPO alone. Pre-treatment with the combination of both rosiglitazone 
and TPO significantly enhanced platelet ROS generation and pre-treatment with high 
glucose appears to reduce the enhanced ROS generation caused by the presence of 
rosiglitazone (Fig. 14C). I then considered the effect of rosiglitazone on platelet 
mitochondrial membrane potential. Unexpectedly, pre-treatment with rosiglitazone 
actually significantly reduced CRP-XL and thrombin stimulated platelet mitochondrial 
membrane depolarisation in comparison to vehicle (Fig. 14D). Pre-treatment with either 
100 ng/mL TPO or 25 mM glucose does not appear to affect the inhibition of platelet 
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Figure 13: Rosiglitazone inhibits platelet aggregation. The effect of 100 μM 
rosiglitazone (10 minute incubation) on washed human platelet (2x10
8
 cells/mL) maximum 
aggregation, stimulated with (A) 3 μg/mL CRP-XL and (B) 2 μM PAR1-AP. N=4. Paired 
students t-test was performed. (C+D) Representative aggregation traces. (E+F) Representative 
aggregation traces showing the effect on 3 μg/mL CRP-XL or 2 μM PAR1-AP stimulated 
platelet aggregation of pre-treatment with 100 μM rosiglitazone or vehicle (DMS0) for 10 




Figure 14: The effect of Rosiglitazone on P Selectin expression and Integrin actication. 
Washed human platelets (2x10
7
 cells/mL) were treated with 100 μM rosiglitazone and the effect 
on CRP-XL and PAR1-AP stimulated (C) p-selectin expression and (D) integrin activation 
compared to vehicle (DMSO) were recorded after 10 minutes of stimulation. N=3. (E)The effect 







Figure 15: The effect of Rosiglitazone on platelet priming and function. (A) Washed 
human platelets were stimulated with 5 μg/mL CRP-XL and thrombin (0.01 - 3 U/mL) for 5 
minutes. The percentage of platelets expressing PS was recorded for each concentration of 
thrombin and plotted as a dose-response curve. N=6. (B) The EC50 value for each condition. 
N=6. A one-way ANOVA with a Dunnett’s post hoc test was performed. . (F)The effect of TPO, 
high glucose and rosiglitazone on 3 μg/mL CRP-XL and 1 U/mL thrombin stimulated 
mitochondrial membrane potential over a 5 minute stimulation period. N=6. Platelets were 
incubated with either 5.5 mM glucose or 25 mM glucose for 10 minutes, 100 μM rosiglitazone or 
vehicle (DMSO) for 10 minutes and vehicle (HT) or 100 ng/mL TPO for 5 minutes prior to being 




Platelet hyperreactivity is a known cause of increased CVD risk and understanding 
the mechanisms behind this enhanced reactivity is fundamental to finding a solution 
and reducing CVD risk. This study aimed to investigate the cause of platelet 
hyperreactivity seen in diseases such as DM. The initial investigation into the effects of 
hyperglycaemia on platelets showed that high glucose concentrations enhanced a 
number of platelet functions, including PS exposure, but had no effect on agonist-
mediated aggregation. I was also able to further add to the literature regarding the 
ability of TPO to enhance platelet activity. Interestingly, this study has demonstrated 
that there is no cumulative effect seen when platelets are treated with TPO in 
combination with high glucose. The final aim of this study was to explore the idea that 
anti-diabetic treatments are able to reverse hyperreactive qualities induced by TPO 
and/or hyperglycaemia.  
Hyperglycaemia has no effect on platelet aggregation but enhances PS 
exposure 
This study has shown that for CRP-XL or PAR1-AP stimulated platelet aggregation 
there is no significant difference between platelets that were pre-incubated with a high 
glucose concentration (25 mM) or a normal glucose concentration (5.5 mM) (Fig. 5). 
This data contradicts the research done by Tang et al who showed that collagen 
stimulated aggregation was enhanced when platelets were pre incubated with high 
glucose (Tang et al., 2011) and other studies with similar results (table 2). There have 
been several studies that also demonstrated that high glucose alone has no effect on 
platelet aggregation (Kobzar, Mardla & Samel, 2011; Kobzar, Mardla & Samel, 2017). 
The reason for such large variance in the literature is most likely down to the vast 
range of ways in which the platelets are subjected to increased glucose levels. For 
example, some studies use hyperglycaemic clamps in healthy and diabetic controls 
where as others simply use very acute hyperglycaemic treatment in washed healthy 
human platelets. In general, the incubation of platelets with high glucose resulted in 
large variance in my experiments and I believe this may be due to the wide range of 
blood glucose levels experienced by different volunteers prior to blood donation. And 
this is likely to have contributed to some of the variability seen in the present study.  
Here, for the first time, I have shown that hyperglycaemia directly results in 
increased platelet exposure of PS (Fig. 8A) and mitochondrial membrane 
depolarisation (Fig. 9D). Increased ROS generation has been shown to enhance 
MPTP formation and PS exposure in platelets. However, it has also been 
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demonstrated that ROS generation is independent of MPTP formation and that it 
requires extracellular calcium entry (Choo, Saafir, Mkumba, Wagner & Jobe, 2012), 
suggesting that ROS generation can lead to PS exposure, but it is not fundamental. 
Here I have shown that hyperglycaemia significantly increases mitochondrial 
membrane depolarisation (Fig. 9D) and has no significant effect on ROS generation 
(Fig. 9B), further adding to the evidence that ROS generation is not essential for PS 
exposure. 
It is well understood that extracellular calcium levels and elevated cytoplasmic 
calcium levels play an important role in the regulation of high-level PS exposure 
(Heemskerk, Vuist, Feijge, Reutelingsperger & Lindhout, 1997). However, Choo et al 
showed that mitochondrial membrane depolarisation is more closely linked to an 
increase in PS exposure than increased calcium signalling. And that MPTP formation 
driven PS exposure is not due to a change in cytosolic calcium levels (Choo, Saafir, 
Mkumba, Wagner & Jobe, 2012). This study has shown that hyperglycaemia inhibits 
platelet calcium signalling (Fig. 10C+D) which coincides with the idea that ROS 
generation is highly calcium dependent and MPTP formation and PS exposure are not. 
Taken together this data suggests that PS exposure can be initiated via a calcium 
dependent, ROS generation dependent pathway or a calcium independent, MPTP 
formation dependent pathway. This data contradicts the results shown by Liu et al, 
where they demonstrated that hyperglycaemia enhances calcium influx (Liu et al., 
2008). This could potentially be explained by the fact that they incubated the platelets 
with 25 mM glucose for 60 minutes prior to stimulation whereas in the present study 
platelets were only incubated with glucose for 10 minutes and the fact that the cell-
permeable diacylglycerol analog, 1-oleoyl-2-accetyl-sn-glycerol (OAG) was used to 
stimulate platelets as opposed to dual stimulation with thrombin and CRP-XL used in 
this study.  
Aoki et al (Aoki et al., 1996) showed that patients with poorly glycaemic-controlled 
non-insulin-dependent diabetes had elevated platelet dependent thrombin generation. 
It would therefore be interesting to investigate the effect of hyperglycaemia on platelet-
dependent thrombin generation. Agbani et al (Agbani, Williams, Hers & Poole, 2017) 
showed that an increase in the local thrombin concentration can lead to ballooning of 
the platelet membrane in platelets at the outer layer of the thrombus. If platelet derived 
thrombin generation is increased by hyperglycaemia then it would be interesting to 
research the effects of hyperglycaemia on platelet membrane ballooning. 
Unlike several previous studies (table 2), I was unable to conclusively show that 
platelet incubation with high glucose can rescue the inhibitory effects of aspirin on 
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platelet aggregation (Gresele et al., 2010; Kobzar, Mardla & Samel, 2017; Le Guyader, 
Pacheco, Seaver, Davis-Gorman, Copeland & McDonagh, 2009; Russo et al., 2012). 
The data collected in this study shows a trend in an increase in platelet aspirin inhibited 
aggregation in the presence of 25 mM glucose but there is no statistical significance to 
this trend (Fig. 11A). For most donor’s high glucose appeared to rescue the inhibitory 
effects of aspirin however for a minority of donors no effect of high glucose was seen. 
There are a few explanations as to why this might be; aggregation is a very variable 
assay in general which could explain large error bars and lack of significance. 
However, it is probably more likely to be due to varying blood glucose levels due to 
reasons previously mentioned. These different conditions could affect how sensitive 
the platelets are to the high glucose added during the experiment. A potential way 
around this would be to ask donors to avoid eating 12 hours prior to blood donation 
(don’t have breakfast until after donation). A more practical solution may be to use a 
blood glucose monitor to test donor’s glucose levels prior to donation and only take 
blood from donors with blood glucose levels within a pre-determined range. 
TPO enhances platelet aggregation and PS exposure 
This study has conclusively shown that TPO is able to enhance platelet function. In 
line with previous studies (Blair, Moore & Hers, 2015; Oda et al., 1996), washed 
human platelets treated with TPO showed elevated aggregation in response to agonist 
(Fig. 6A+B). The present study has shown, for the first time, that TPO is also able to 
significantly enhance platelet PS exposure (Fig. 7B). Interestingly, TPO only enhances 
PS when the platelets are stimulated for 5 minutes but has no effect when they are 
stimulated for 10 minutes - this suggests that TPO accelerates the rate at which 
platelets expose PS rather than increasing the maximum amount of PS that is 
exposed. Interestingly, when the platelets were treated with both a high concentration 
of glucose and TPO, no cumulative effect was seen (Fig. 8C). This would therefore 
suggest that both glucose and TPO enhance PS via a similar mechanism.  
The present study has demonstrated that TPO causes an increase in mitochondrial 
membrane depolarisation (Fig. 9D). And figure 10 A+B shows that TPO has no effect 
platelet calcium mobilisation further adding to the theory that PS exposure does not 
rely on an increase in calcium signalling. Unlike hyperglycaemia, platelets treated with 
TPO expressed increased ROS generation (Fig. 9A) as well as mitochondrial 
membrane depolarisation and PS exposure. 
Mitchell et al investigated the ability of c-Mpl receptor agonists (such as TPO) to 
protect platelets from apoptosis. They discovered that platelets did in fact show 
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resistance to apoptosis when treated with c-Mpl agonists, but this effect only appeared 
during the first week of therapy (Mitchell et al., 2014).  This suggests that in vivo TPO 
is also able to accelerate platelet function or the effects of TPO are time limited. The 
authors concluded that c-Mpl agonists are able to induce transient signalling through 
the phosphoinositide 3-kinase (PI3-kinse) pathway leading to activation of the 
serine/threonine kinase PKB in vivo. PKB signals to over 100 proteins, but it's overall 
effect is pro-survival (Downward, 2004). Pasquet and colleagues have shown that the 
PI 3-kinase pathway is important in the priming action of TPO in response to collagen 
(Pasquet et al., 2000) and Blair et al have shown that platelets treated with TPO show 
significantly enhanced thrombus formation on a collagen-coated surface compared to 
platelets treated with vehicle (Blair et al., 2018). Interestingly, they demonstrated that 
p110α, a PI 3-kinase isoform, negatively regulates TPO-mediated enhancement of 
platelet function. However, as their experiments were carried out under non-
coagulating conditions a link between the ability of TPO to enhance thrombin 
generation, demonstrated by Blair et al and its ability to increase platelet PS exposure 
cannot be made from these studies alone.  
Combining all of this information and the data shown in the present study, I believe 
that this provides sufficient evidence to suggest that TPO is able to enhance the 
agonist-mediated pro-thrombotic exposure of PS by enhancing the generation of ROS 
leading to the formation of MPTPs and mitochondrial membrane depolarisation. 
Perhaps via the PI 3-kinase / PKB pathway. Interestingly, it has been reported that 
thromboxane production, calcium homeostasis and PI 3-kinase signalling are not 
involved in hyperglycaemia-related platelet hyperreactivity (Sudic, Razmara, Forslund, 
Ji, Hjemdahl & Li, 2006). This could perhaps explain the different effects of TPO and 
high glucose on intracellular calcium levels and ROS generation. The effects of TPO 
and glucose on platelet PS exposure demonstrated by this study are summarised in 
figure 16. 
The mechanisms involved in platelet aggregation are distinct from those involved in 
platelet PS exposure. This study has clearly shown that TPO is able to enhance both 
aspects of platelet function whereas acute hyperglycaemia is only able to enhance the 





Figure 16: Summary figure showing the effect of Glucose and TPO on platelet PS 
exposure. Under highly stimulating conditions (e.g. Dual stimulation with CRP-XL and 
thrombin) platelets express greater levels of PS. The results of this study suggest that 
TPO is able to enhance this increase in PS exposure via an increase in ROS 
generation and an increase in mitochondrial permeability transition pore formation 
leading to an increase in calcium concentration and scramblase activity. Glucose on 
the other hand has no effect on platelet ROS generation and only causes an increase 
in platelet PS exposure via the depolarisation of the mitochondrial membrane resulting 
in an increase in calcium, leading to increased scramblase activity and PS exposure. 
Interestingly, this study has also shown that glucose reduces overall platelet calcium 
signalling, but calcium is known to be an important component of PS exposure and a 
direct result of mitochondrial membrane depolarisation. These contradictory results 
could be explained by the idea that glucose still causes an increase in local calcium 
signalling resulting in PS exposure, but an overall decrease in calcium signalling within 
the whole cell.  
Metformin has no significant effect on platelet aggregation 
Xin et al (Xin et al., 2016) have shown that metformin is capable of inhibiting 
platelet function. The results of this study shows a trend that suggests that metformin 
reduces platelet aggregation, however these results did not reach significance. It is 
likely that with a higher powered study it could be proved that metformin significantly 
inhibits platelet aggregation. However, unlike Xin et al, I found that metformin has no 
effect on integrin αIIbβ3 activation and P-selectin expression (Fig. 12E+F). Further 
investigation into the effects of metformin on platelet function is required.   
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 Although the human proteome map shows the OCT1 transporter being present in 
human platelets (Fig. 4), there is still little evidence to suggest that metformin is able to 
cross the platelet cell membrane. Future work therefore needs to be carried out with 
regards to metformin and platelet function. I would suggest confirming that metformin is 
in fact able to enter platelets before continuing research into its effect on platelets. A 
potential way around this would be to look at the effects of phenformin, another 
biguanide, on platelet function as it has a much faster mechanism of action and is 
known to be able to cross the cell membrane (Bridges, Sirviö, Agip & Hirst, 2016). 
Phenformin was a drug produced before metformin but was quickly removed from the 
market due to toxicity reasons, mainly severe lactic acidosis (Assan, Heuclin, Girard, 
LeMaire & Attali, 1975). However, it would still be useful to investigate its effects on 
platelet function as a good indicator of metformin action. Firstly, in order to confirm 
phenformin is working I would suggest using western blotting to monitor AMPK 
regulation as phenformin has been shown to highly upregulate AMPK (Kim, Yang, Kim 
& Ha, 2016; Yang, Sha, Davisson & Qi, 2013).  
Rosiglitazone inhibits platelet aggregation and enhances PS exposure. 
In accordance with data shown by Liu et al (Liu, Park, Chang, Huh, Lee & Lee, 
2016) this study has shown that platelet incubation with the anti-diabetic drug, 
rosiglitazone, significantly inhibits agonist-stimulated platelet aggregation (Fig. 13). 
Platelets treated with rosiglitazone showed reduced integrin activation and p-selectin 
expression, however this did not reach significance (Fig. 14A+B) this is probably due to 
the fact that this study was under-powered and further analyses need to be performed. 
Interestingly, the presence of rosiglitazone is enough to inhibit the enhancement of 
aggregation seen by TPO (Fig. 13C), suggesting that even in a hyper reactive state 
rosiglitazone is able to inhibit platelet aggregation.  
On the contrary, rosiglitazone significantly enhanced platelet PS exposure (Fig. 
15A+B) and increased platelet generation of ROS (Fig. 15C). Surprisingly, this study 
has also shown that treatment with rosiglitazone causes a significant reduction in 
mitochondrial membrane depolarisation (Fig. 14D). This is a strange phenomenon 
because both agonist-mediated and apoptotic PS exposure supposedly require 
mitochondrial membrane depolarisation. This would therefore suggest that PS 
exposure can be initiated by a calcium-dependent ROS generation pathway or by a 
calcium independent mitochondrial membrane depolarisation pathway.  In order to 
confirm this it would be interesting to investigate the effects of rosiglitazone on platelet 
calcium mobilisation.  
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Contradictory to the data confirming the ability of rosiglitazone to inhibit platelet 
function, this study has also shown that rosiglitazone is able to significantly enhance 
platelet function in terms of ROS generation and PS exposure. This could provide a 
potential mechanism behind the increased risk of cardiac event seen in patients 
prescribed rosiglitazone (Cheng, Gao & Li, 2018). 
 Future works 
A better understanding of the mechanism behind glucose entry into the platelet and 
information on time scale could be investigated using 2-NBDG, a fluorescent glucose 
analogue (Zou, Wang & Shen, 2005), which can be used to monitor glucose uptake 
into platelets using flow cytometry. GLUT3 translocation could also be monitored using 
a fluorescently tagged GLUT3 antibody.  
Platelets in patients with diabetes are not simply exposed to high levels of blood 
glucose but there are many other factors that could be contributing to the increased 
platelet hyperreactivity observed. I would be very interested in investigating the effects 
of glucose and TPO on diabetic mice and/or patients and compare the results to 
healthy controls.  
In order to further the work on the ability of TPO to enhance platelet function I 
would suggest investigating the effect of TPO on thrombin generation and membrane 
ballooning. As an increase in PS exposure should lead to an increase in thrombin 
generation which in turn would lead to an increase in membrane ballooning. This would 
also be worth investigating in terms of the effect of hyperglycaemia on platelet function. 
One way of testing the theory that the increase in PS exposure is PI 3-kinase 
dependent would be to repeat the same experiments but in the presence of the PI 3-
kinase inhibitor wortmannin. Using western blotting to monitor PI 3-kinase activity, PKB 
and other potential downstream signalling events in order to reveal the mechanism of 
action. It would also be interesting to investigate whether PS exposure can be 
mediated by ROS generation or mitochondrial membrane depolarisation independently 
of each other. This could be done by stimulating PS exposure whilst, for example, 
simultaneously inhibiting platelet ROS generation. In addition to these suggested 
experiments, animals’ models could be used to investigate the effects of 
hyperglycaemia and increased serum levels of TPO in vivo. 
Conclusion 
Increased serum levels of TPO and glucose are associated with various clinical 
conditions and will contribute to platelet hyperreactivity and consequently increased 
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risk of cardiovascular disease. Further research into the mechanism behind this is 
required in order to address anti platelet resistance seen in diseases such as diabetes. 
Metformin has shown some promising evidence to suggest its capabilities as an anti-
platelet therapy alternative, however confirmation of its ability to enter platelets and 
inhibit function is necessary. Rosiglitazone is still used as an anti-diabetic treatment in 
the US but has been removed from the European market due to an increased risk of 
cardiovascular disease, the results from this study may suggest a potential explanation 
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